Ultra-low-dose immunotherapy doubles survival in head and neck cancer, study finds

Ultra-Low-Dose Nivolumab Doubles Survival in Head and Neck Cancer

A low-cost regimen combining ultra-low-dose nivolumab with oral metronomic chemotherapy nearly doubled median overall survival compared with standard platinum-based chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma, according to phase 3 results presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago.ascopubs

An Affordable Alternative

The trial, which enrolled 422 patients with recurrent or metastatic HNSCC, found that the regimen known as TMC-I — triple metronomic chemotherapy plus ultra-low-dose nivolumab — achieved a median overall survival of 10.3 months compared with 6.2 months for platinum-based chemotherapy. The combination also doubled objective response rates and produced fewer severe adverse events than standard treatment.hmpgloballearningnetwork

The results build on years of research from investigators at India’s Tata Memorial Centre in Mumbai, where oncologists Vijay Patil, Vanita Noronha, and Kumar Prabhash have pioneered the use of dramatically reduced doses of nivolumab — roughly one-tenth of the standard dose approved in the United States and Europe — combined with inexpensive oral chemotherapy agents. The TMC-I regimen consists of oral celecoxib, weekly methotrexate, and erlotinib alongside intravenous nivolumab at a 20 mg flat dose every three weeks.ascopost

Addressing a Global Access Gap

Bristol-Myers Squibb’s nivolumab, marketed as Opdivo, typically costs thousands of dollars per infusion at standard doses. The ultra-low-dose approach reduces the monthly cost of immunotherapy to approximately the equivalent of $230, making it accessible to the vast majority of head and neck cancer patients in low- and middle-income countries, where an estimated 1% to 3% of patients can afford full-dose checkpoint inhibitors.cancer

Head and neck squamous cell carcinoma is disproportionately common in South Asia and sub-Saharan Africa. In India alone, it accounts for roughly one-third of all cancer diagnoses, and most patients present with advanced disease.moneycontrol

Building on Prior Evidence

The current first-line trial follows earlier work by the same group. A prior phase 3 study published in the Journal of Clinical Oncology in 2022 showed that adding low-dose nivolumab to triple metronomic chemotherapy improved one-year overall survival from 16.3% to 43.4% in pretreated patients, with a 45% reduction in the risk of death. Long-term follow-up presented at ASCO 2024 demonstrated that those benefits persisted beyond 2.5 years, with the TMC-I arm tripling overall survival at that timepoint.ascopubs

“To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved overall survival and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors,” the investigators wrote of the initial trial.ascopubs

The new data, now demonstrating benefit in the first-line platinum-sensitive setting with a 44% reduction in the risk of death, position TMC-I as a practical treatment option where standard immunotherapies remain out of reach.cancernetwork